					LIET 5 5 TO		U.S. Palent and Trademan	K Onice; U.S. D	EPARIMENT OF	COMME	HUE		
	Substitu	te fo	form 1449A	VPTO (	FAT & TRADEN	*	Appi	ication Numb r	10/663,061 S ptember 12, 2003				
				0 N E	TRADEM	EUDE CUDE	Filin	g Date					
Ì					ISCLO		First	Named Inventor	Charl s N. S rhan				
ı	ST				APPLI		Art U	Jnit	1621				
ı		(u	se as many	/ sheets	as necessa	DY)	Exan	niner Name	5. Kumar				
ı	Sheet		1	of	5		Atto	rney Docket Number	7213.13				
			<u></u>		L	U.S. PAT	ENT	DOCUMENTS		7			
1	"Examiner	CT:	DOC	IMENT N	ILIMBER	D. blication	0-1-	Name of Patente		Pages, Colur Where Relevan			
	triziale.	DOCUMENT NUMBER  Number - Kind Code (if known)				Publication MM-DD-Y		Applicant of Cited Do		Relevant Figu			
1	Br		US- 4,	,666,701		5/19/1987		Horrobin et al.					
1	Ka	_	US- 5,	409,955	5	4/25/1995		Bockow et al.					
		_	US- 5,	,411,988	3	5/2/1995		Bockow et al.					
	7	/2	US- 5,	,709,855	5	1/20/1998		Bockow	<u> </u>	<u> </u>			
			US- 6,	,201,022	2	3/13/2001		Mease et al.					
1			US- 4	,201,211	<u> </u>	5/6/1980		Chandrasekaran et al.					
1			US- 5,	,814,599	9	9/29/1998		Mitragotri et al.				_	
4	1/2			,846,974		12/8/1998		Kaliman et al.					
1	_		US- 4	,810,424	ļ 	3/7/1989		Gerwick, et al.					
1			US-								_		
	\\		US-	$\overline{\lambda}$									
			US-				_						
			US-										
	1		US-			<u> </u>				l			
	•				F(	DREIGN P	ATE	NT DOCUMENTS	1	· · · · · · · · · · · · · · · · · · ·	Ī		
			FOREIGN	I PATENT	DOCUMENT								
1	"Examiner	9	Country		r - Kind Code	Publication D	Date	Name of Patentee or		olumns, Lines, evant Passages	TRANSL	ATTON	
	tritial	No.	Code:	L `	known)	MM-DD-YY		Applicant of Cited Document		Figures Appear	YES	NO	
	Un		wo	91/169		11/14/199							
4		6	WO	98/465		10/22/1998							
1		L	JP .	51863		7/27/1993		Bunshiyou et al.	<u> </u>		Ø		
	1	002404773							=				
A	1	L`							-			므	
	/			_	-//-				ļ		<u></u>	므	
	/		<u> </u>		1/2	2			<u> </u>				
	EXAMI	NER	SIGNATU		THA	Kays	>   1	DATE CONSIDERED	5M	109			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEF 609. Draw line to citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											line thro	ough	

	Substitu	te for fo	rm 1449A/PTO	PADEWARK OF	Applicati n Numb r	10/663,061				
	11.15		AATION D		Filing Date	Sept mber 12, 2002				
				ISCLOSURE ADDITIONS	First Named Inv ntor	Charles N. S rhan				
	51			APPLICANT	Art Unit	[6/2]				
		(use	as many sheets	as necessary)	Examiner Name	S. James	~			
	Sheet	2	of	5	Attorney Docket Number	7213.13				
	OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS									
ı	*Examiner	Cito	Include na	arne of the author (in CAPITAL	LETTERS), title of the article (when a symposium, catalog, etc.), date, pag	appropriate), title of the	TRANSLATION			
ı	indiale	No.		number(s), publish	er, city and/or country where published	d	YES	NO		
	4		PCT/US01/051	96 International Search	Report					
		7	J.W. Karanian XP-002200246		ctions of hydroxy - docosahex	aenoic acid", Abstract,				
	1		E.M. Hill, et al. "Identification and egg hatching activity of monohydroxy fatty acid eicosanoids in the barnacle Balanus balanoides", Abstract, XP-002200247, 1992							
1			L. De Montarby, et al. "Synthesis stereoselectives de metabolites hydroxyles d'acides gras polinsatures", Bulletin De La Societe Chimique de France, No. 3, pgs. 419-432, 1989.							
		M. Yamane, et al., "Docosahexaenoic/arachidonic acid ω-hydroxylation system and differentiation in the human clonic adenocarcinoma cell line, Caco-2", Cancer Letters, Vol. 122, pgs. 51-59, 1998.								
1		7			Insaturated Fatty Acids Using III. Chem. Soc. Jpn. Vol. 69, p					
		/		"Proceedings of the AO American Oil Chemists' S	CS Short Course on Polyunsa Society 1987.	turated Fatty Acids and				
		y		Inhibitory effects of doco : J. Cancer, 1997, pgs. 6	sahexaenoic acid on colon ca 550-655.	rcinoma 26 metastasis				
		V		al., "Prevention of suddings", Circulation 99 1999	en cardiac death by dietary pu ), pgs. 2452-2457.	re ω-3 polyunsaturated				
1		1	omega-6 and o	mega-3 fatty acids", J. A	sentiality of an recommended Am. Coll. Nutr. 1999, pgs. 487-	489.				
1			R. Marchioloi, after myocardia	Dietary supplementation	with n-3 polyunsaturated fatt e GISSI-Prevenzione trial", <i>La</i>	y acids and vitamin E ncet 1999, pgs. 447-455.	ĘĮ \			
4	EXAMI	NER SI	GNATURE	la Milas	DATE CONSIDERED	SUN / M				
I	*EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

Subst	itute fo	r for	m 1449A/	PTO	THE SE	Application Number	10/663,061		
		-	# A TIC	n	MADENIARY AND	Filing Date	Sept mber 12, 2003		
					ISCLOSURE	First Named Inventor	Charles N. Serhan		
5					APPLICANT	Art Unit	1625		
	(U	SØ &	as many	sneets	as necessary)	Examiner Name	S. Jennes		
Sh	et	3		of	5	Attorney Docket Number	7213.13		
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS									
*Examine	Cla		t	nclude n	ame of the author (in CAPITAL	LETTERS), title of the article (when a ly symposium, catalog, etc.), date, pag	appropriate), title of the	TRANS	LATION
tritiale	No.	Ī			number(s), publish	er, city and/or country where publishe	96(3), Volume issue 9d	YES	NO
	1		G. Weis	smann	, "Aspirin", <i>Sci. Am.</i> 199	1, pgs. 84-90.			
//			Basic P	rinciple	s and Clinical Correlates				
		7	J. Claria endothe	et al., elial cel	"Aspirin triggers previou l-leukocyte interactions",	sly undescribed bioactive eico Proc. Natl. Acad. Sci. USA 19	sanoids by human 995, pgs. 9475-9479.		
		7	C.N. Serhan et al, "Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils", <i>Biochemistry</i> 1995, pgs. 14609-14615.						
	<b>1</b>		N. Chia lipoxins	N. Chiang et al., "Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion", <i>J. Clin. Invest.</i> 1999, pgs. 309-316.					
		1	H.R. He	erschma is", <i>Tre</i>	an, "Recent progress in tends Cardiovasc. Med. 1	the cellular and molecular biology 998, pgs. 145-150.	ogy of prostaglandin		
			P. Need	ileman	et al., "The discovery ar	d function of COX-2", J. Rheu	imatol 1997, pgs. 6-8.		
			and mu	rine pe	I., "Aspirin-triggered 15-c ritonitis exudates: Devel p. Ther. 1998, pgs. 779-	epi-lipoxin A4 (ATL) generation opment of a specific 15-epi-LX 790.	n by human leukocytes (A4 ELISA", <i>J</i> .		
			G. Xiao	et al.,	'Analysis of hydroperoxi	de-induced tyrosyl radicals an synthase-2", <i>Biochemistry</i> 19	d lipoxygenase activity in 97, pgs. 1836-1845.		
			K. Node et al., "Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids", Science 1999, pgs. 1276-1279.						
		7	S. Seth natural	i et al., anti-fla	"Inhibition of phagocyte- rimatory mechanism?"	endothelium interactions by o d. Dab. Clin. Med. 1996, pgs. 2	xidized fatty acids: A 27-38.		
EXA	MINEF	SIC	GNATUR		Wan Mar	DATE CONSIDERED	Sont 100	4	
*EX	AMINE on if n	R: ot in	Initial if	reference an	e considered whether of id not considered. Includ	or not citation is in conformation copy of this form with next cor	with MPEP 809. Draw	line th	rough

TRANSLATION

YES

NO

P.N Me

01PE 48 3

Substitute for form 1449A/PTO

She t

No.

EXAMINER:

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

5

cancer", FASEB J. 1997, pgs. 234-247.

Application Numb r	10/663,061	
Filing Dat	Sept mb r 12, 2003	
First Named Inventor	Charl s N. S rhan	Ī
Art Unit	162)	
Examiner Name	S- Kinner	
Attorney Docket Number	7213.13	

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

G.N. Levy, "Prostaglandin H synthases, nonsteriodal anti-inflammatory drugs, and colon

		k. Gronert, et al., "Transcellular regulation of eicosanoid biosynthesis", Eicosanoid Protocols 1999, pgs. 119-144.		
		H.J. George et al., "Expression purification and characterization of recombinant human inductible prostaglandin G/H synthase from baculovirus-infected insect cells", <i>Protein Expres. Purif.</i> 1996, pgs. 19-26.		
1		J.H. Capdevila et al., "The highly stereoselective oxidation of polyunsaturated fatty acids by cytochrome P450BM-3", <i>J. Biol. Chem.</i> 1996, pgs. 22663-22671.		
		R.T. Ruettinger et al., "Epoxidation of unsaturated fatty acids by a soluble cytochrome P-45-dependent system from bacillus megaterium", <i>J. Biol. Chem.</i> 1981, pgs. 5728-5734.		
1		T.H. Lee et al., "Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product", J. Biol. Chem. 1984, pgs. 2383-2389.		
		C.N. Serhan et a;., "Nomenclature of lipoxins and related compounds dervived from arachidonic acid and eicosapentaenoic acid", <i>Prostaglandins</i> 1987, pgs. 201-204.		
		D.J.Hill et al., "Trout thrombocytes contain 12-but not 5-lipoxygenase activity", <i>Biochim. Biophys. Acta</i> 1999, pgs. 63-70.		
		8.N. Cronstein et al., "A mechanism for the anti-inflammatory effects of corticosteriods: The glucocorticoid receptor regulates leukocyte adhesion to endotheliasl cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1", Proc. Natl. Acad. Sci. 1992, pgs. 9991-9995.		
		T. Yokomizo et al., "A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis", Nature 1997, pgs. 620-624.		
		M.R. Buchanan eval., "Regulation of endothelial cell and platelet receptor-ligand binding by the 12- and 15-lipoxygenase monohydrexides, 12-, 15-HETE and 13-HODE", Prostaglandins Leukot. Essent. Fatty Acids 1998, pgs. 329-346.		
EVAMIN	VIED CI	GNATING DATE CONSIDERED 18	2/	

thitial if serence considered whether or not citation is in conformance with MPEP 609. Draw line through

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Substitu	Substitute for form 1449A/PTO  INFORMATION DISCLOSURE					Application Numb r	10/663,061		
	1815					ICCI OCUBE	Filing Dat	S ptemb r 12, 2003		
						_	First Named Inventor	Charles N. Serhan		
	(use as many sheets as necessary)						Art Unit	1621		
							Examiner Name	S. Kumal	<b>1</b>	
	Sheet		5		of	5	Attorney Docket Number	7213.13 <sup>°</sup>		
				OTI	HER C	OCUMENTS - NON	I-PATENT LITERATURE	DOCUMENTS		
	Examiner Initials	Cite No.		l,	nclude na item (t	ook magazine, journal, serial	LETTERS), title of the article (when a l, symposium, catalog, etc.), date, pag er, city and/or country where publishe	ge(s), volume-issue	TRANS	ATION
		K		P.M. Ric healthy	dker et men", /	al., "Inflammation, aspiri V. Engl. J. Med. 1997, p	n, and the risk of cardiovascul gs. 973-979.	ar disease in apparently		
-			<del>}</del>	Commu	nication	n Relating to the Results	of the Partial International Se	arch		
	1	2		Takeshi	Terano	o, Ensho, Chemical Abs	tract 107:22439, pp. 63-71, 19	87.		0
1				Miller et	al., Lip	ids, Chemical Abstract	112:117062, pp. 998-1003, 19	89.		
		1	1	Hill, EM	. Proc f	R. Soc. London Ser. B.,	247 (1318) pp 41-46, 1992.			
	1									
	1				$\overline{}$					
					<u> </u>	0/		0		
						1 n l	<i>y</i>			
	EXAM	NEF	SI	GNATUR		if Alla	B DATE CONSIDERED	Det 1	104	
	*EXAM citation	INE if no	R: ot in	Initial if	referenc	e considered whether of not considered. Include	not citation is in conformance copy of this form with next cor	e with MPEP 609. Draw nmunication to applicant.	line th	rough

PTO/SB/08A (10/01) (modified) -

		or 1 2 2003 m	U.S. Patent and Trademar	k Office; U.S. DEPARTMENT OF	СОММ	ERCE					
Substitute for	form 1449A/PTO	DISCH OSUBE	Application Numb r	10/663,061							
INFOR	ALATION!	RADEWIN	Filing Date	S ptember 12, 2003							
	IMMINOIT		First Named Inv ntor	Charles N. Serhan	Charles N. Serhan						
		APPLICANT	Art Unit	1625							
(us	e as many sheet	s as necessary)	Examiner Name	S. Jumas							
She t	1 of	1	Attorney Docket Number	7213.13							
	OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
Examiner Cite	Include	name of the author (in CAPITAL	LETTERS), title of the article (when a symposium, catalog, etc.), date, page	appropriate), title of the ge(s), volume-issue	TRANSLATION						
Indiate Da		number(s), publish	er, city and/or country where publishe	od	YE\$	NO					
1	Acid. Alone	al., "Effects of Highly Co and Combined, on Bleed 9 (8-9), pp. 97-101, 1989	ncentrated Omega-3 PUF A ling Time and Serum Liquid	s and Acetylsalicylic Profile", <i>J, Olso City</i>							
	lacovietto et	al. "Modulation of Fibri	nolytic Response to Venous rin and n-3 PUFAs", <i>Arterio</i> s	Occlusion in Humans scierosis Thrombosis,							
1	Laust al., "E	iffects of Fish Oil Supple Requirement in Patien	ementation on Non-Steroida ts with Mild Rheumatoid Art Journal of Rheumatology, Vo	thritis - A Double-Blind							
	Rao et al. "C	omparative Pharmacolo Prostaglandins Leukot. I	gy of Cyclooxygenase inhit ned., Vol. 18 (1), pp. 119-131	oitors on Platelet , 1985							
7	í										
		1/ 1									
EXAMINER	SIGNATURE	of Man	A DATE CONSIDERED	SUPT-104	1						
*EXAMINEF	*EXAMINER: Initial it reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										